A Recombinant VSV-vectored Vaccine Rapidly Protects Nonhuman Primates Against Lethal Nipah Virus Disease

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2022 Mar 14

PMID 35286211

Authors

Stephanie L Foster

Courtney Woolsey

Viktoriya Borisevich

Krystle N Agans

Abhishek N Prasad

Daniel J Deer

Joan B Geisbert

Natalie S Dobias

Karla A Fenton

Robert W Cross

Thomas W Geisbert

Affiliations

Soon will be listed here.

Abstract

SignificanceConcern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.

Citing Articles

Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics.

Spengler J, Lo M, Welch S, Spiropoulou C Clin Microbiol Rev. 2024; 38(1):e0012823.

PMID: 39714175 PMC: 11905374. DOI: 10.1128/cmr.00128-23.

Establishing an immune correlate of protection for Nipah virus in nonhuman primates.

Leyva-Grado V, Promeneur D, Agans K, Lazaro G, Borisevich V, Deer D NPJ Vaccines. 2024; 9(1):244.

PMID: 39702562 PMC: 11659318. DOI: 10.1038/s41541-024-01036-2.

Risk Evaluation and Mitigation Strategies for Potential Outbreaks of Nipah Virus Infection: Evidenced by the Recent Incidences in Southeast Asian Countries.

Rahman M, Shanjana Y, Cronmiller S, Zong D, Davis R, Ernest J Health Sci Rep. 2024; 7(12):e70239.

PMID: 39633840 PMC: 11615790. DOI: 10.1002/hsr2.70239.

Generation, Recovery, and Propagation of a Recombinant Vesicular Stomatitis Virus Expressing the Marburg Virus Glycoprotein.

Anhalt H, Marzi A Methods Mol Biol. 2024; 2877:67-74.

PMID: 39585614 DOI: 10.1007/978-1-0716-4256-6_5.

Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus.

Moon S, Flores R, Yim M, Lim H, Kim S, Lee S Vaccines (Basel). 2024; 12(9).

PMID: 39340029 PMC: 11436239. DOI: 10.3390/vaccines12090999.

References

Tan C, Goh K, Wong K, Sarji S, Chua K, Chew N . Relapsed and late-onset Nipah encephalitis. Ann Neurol. 2002; 51(6):703-8. DOI: 10.1002/ana.10212. View

Prasad A, Agans K, Sivasubramani S, Geisbert J, Borisevich V, Mire C . A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys. J Infect Dis. 2019; 221(Suppl 4):S431-S435. DOI: 10.1093/infdis/jiz469. View

van Doremalen N, Lambe T, Sebastian S, Bushmaker T, Fischer R, Feldmann F . A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Negl Trop Dis. 2019; 13(6):e0007462. PMC: 6581282. DOI: 10.1371/journal.pntd.0007462. View

Chua K, Bellini W, Rota P, Harcourt B, Tamin A, Lam S . Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000; 288(5470):1432-5. DOI: 10.1126/science.288.5470.1432. View

Pejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D . Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. NPJ Vaccines. 2020; 5(1):32. PMC: 7156503. DOI: 10.1038/s41541-020-0179-4. View

Guillaume V, Contamin H, Loth P, Georges-Courbot M, Lefeuvre A, Marianneau P . Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 2003; 78(2):834-40. PMC: 368848. DOI: 10.1128/jvi.78.2.834-840.2004. View

Cong Y, Lentz M, Lara A, Alexander I, Bartos C, Bohannon J . Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus. PLoS Negl Trop Dis. 2017; 11(4):e0005532. PMC: 5397074. DOI: 10.1371/journal.pntd.0005532. View

Jones S, Feldmann H, Stroher U, Geisbert J, Fernando L, Grolla A . Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005; 11(7):786-90. DOI: 10.1038/nm1258. View

Quist-Paulsen E, Aukrust P, Kran A, Dunlop O, Ormaasen V, Stiksrud B . High neopterin and IP-10 levels in cerebrospinal fluid are associated with neurotoxic tryptophan metabolites in acute central nervous system infections. J Neuroinflammation. 2018; 15(1):327. PMC: 6260858. DOI: 10.1186/s12974-018-1366-3. View

10.

Walpita P, Cong Y, Jahrling P, Rojas O, Postnikova E, Yu S . A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines. 2017; 2:21. PMC: 5627259. DOI: 10.1038/s41541-017-0023-7. View

11.

Ang B, Lim T, Wang L . Nipah Virus Infection. J Clin Microbiol. 2018; 56(6). PMC: 5971524. DOI: 10.1128/JCM.01875-17. View

12.

Mathieu C, Guillaume V, Sabine A, Ong K, Wong K, Legras-Lachuer C . Lethal Nipah virus infection induces rapid overexpression of CXCL10. PLoS One. 2012; 7(2):e32157. PMC: 3290546. DOI: 10.1371/journal.pone.0032157. View

13.

Tellez Freitas C, Johnson D, Weber K . T Cell Calcium Signaling Regulation by the Co-Receptor CD5. Int J Mol Sci. 2018; 19(5). PMC: 5983667. DOI: 10.3390/ijms19051295. View

14.

Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N . Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. J Immunol Res. 2021; 2021:6661406. PMC: 7925068. DOI: 10.1155/2021/6661406. View

15.

Bossart K, Crameri G, Dimitrov A, Mungall B, Feng Y, Patch J . Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol. 2005; 79(11):6690-702. PMC: 1112112. DOI: 10.1128/JVI.79.11.6690-6702.2005. View

16.

Huffman A, Lin J, Kim S, Byrne K, Vonderheide R . CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight. 2020; 5(10). PMC: 7259512. DOI: 10.1172/jci.insight.137263. View

17.

McElroy A, Erickson B, Flietstra T, Rollin P, Nichol S, Towner J . Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis. 2014; 20(10):1683-90. PMC: 4193175. DOI: 10.3201/eid2010.140430. View

18.

Ram D, Manickam C, Hueber B, Itell H, Permar S, Varner V . Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog. 2018; 14(5):e1007104. PMC: 5997355. DOI: 10.1371/journal.ppat.1007104. View

19.

Roman R, Tornieporth N, Cherian N, Shurtleff A, LAzou Jackson M, Yeskey D . Medical countermeasures against henipaviruses: a review and public health perspective. Lancet Infect Dis. 2021; 22(1):e13-e27. PMC: 8694750. DOI: 10.1016/S1473-3099(21)00400-X. View

20.

Arunkumar G, Chandni R, Mourya D, Singh S, Sadanandan R, Sudan P . Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018. J Infect Dis. 2018; 219(12):1867-1878. DOI: 10.1093/infdis/jiy612. View